A Double-blind, Multiple-dose, 52-week Study to Evaluate the Efficacy and Safety of Testosterone Enanthate Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism

Trial Profile

A Double-blind, Multiple-dose, 52-week Study to Evaluate the Efficacy and Safety of Testosterone Enanthate Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Testosterone enanthate (Primary)
  • Indications Hypogonadism
  • Focus Registrational; Therapeutic Use
  • Acronyms STEADY
  • Sponsors Antares Pharma
  • Most Recent Events

    • 08 Aug 2017 According to an Antares Pharma media release, data from this trial has been presented at a moderated poster session at the annual American Urological Association meeting 2017.
    • 16 May 2017 According to an Antares Pharma media release, data from the study will be presented at the American Urological Association Annual Meeting 2017.
    • 16 May 2017 Results published in an Antares Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top